This paper describes the term biotechnology and how a small Austrian startup enterprise could enter into foreign markets. The paper combines knowledge of Intercultural and International Management constantly referring to biotechnology.
This paper is divided into 3 major chapters. The second chapter defines biotechnology generally and furthermore gives an insight in marine biotechnology using the example of a concrete enterprise. Afterwards cultural and socio-political particularities in the fields of biotechnology are explained based on Austria where this startup enterprise is headquartered and currently operating. The fourth chapter concentrates on concrete foreign market entry strategies which could be
applied by this startup enterprise. Finally every aspect is summarized and a final recommendation is given.
Table of Contents
1. Introduction
2. Biotechnology
2.1 Modern Biotechnology
2.2 Marine Biotechnology
2.3 SeaLife Pharma
3. Austria
3.1 Austria according to Hofstede
3.2 Austria’s attitude in the fields of biotechnology
4. SeaLife Pharma enters into foreign markets
4.1 Licensing
4.2 Strategic Alliance
4.3 Final Recommendation
5. Conclusion
Research Objectives and Key Themes
This seminar paper examines the challenges and strategies for a small-scale Austrian biotechnology startup, SeaLife Pharma, regarding its potential entry into foreign markets, while specifically considering socio-cultural frameworks and regulatory environments.
- The role and segments of modern biotechnology in the 21st century.
- Exploration of marine biotechnology as an emerging, high-potential sector.
- Cultural analysis of Austria using Hofstede’s dimensions to understand business behavior.
- Regulatory hurdles and societal attitudes toward biotechnology in Europe and Austria.
- Evaluation of market entry strategies such as licensing and strategic alliances for startups.
Excerpt from the Book
2.2 Marine Biotechnology
Currently exploration of oceans by biotechnology experiences a great boom. Hence, almost a dozen of enterprises have been established recently focussing on the research on marine microorganisms in order to develop new drugs such as antibiotics or cancer treatment products. The same has been done with microorganisms living onshore recently. Marine ecosystems are a white hope regarding the development of better as well as more resistant antibiotics. Terrestrial ecosystem are largely explored and well studied. Even the rain forest has been explored. This leads to the conclusion that marine territories currently count as the future research area. Oceans aren’t only the oldest and biggest biosphere but also one of the most competitive areas on earth. Over the course of evolution an enormous diversity of organisms evolved whereas the majority isn’t already explored.
Exploring metabolisms under extreme conditions make blue biotechnology that interesting. 90 per cent of all marine organisms are living among 4° Celsius. Down the road exploring low temperature process proceedings in cells of microorganisms could result in enormous energy savings. Detergents will be produced performing at 30°C the same way as currently at 60°C. Within a million years marine creatures such as sponges or corals adapted to their environment. On a single madrepore, found in the Red sea, researchers lately identified 5.000 new microorganisms located on the surface of that single madrepore.
The tremendous biochemical diversity of marine microorganisms and their biotechnological potential is becoming more and more recognized, not only by microbiologists but also by the pharmaceutical industry. In 2006, Ziconotid has been approved for intensive chronic aches treatment. The Japanese pharmaceutical firm Eisai is selling it under the brand name Prialt.
Chapter Summaries
1. Introduction: This chapter outlines the societal relevance of biotechnology, focusing on the need for innovative solutions against antibiotic-resistant pathogens and the paper's scope.
2. Biotechnology: Provides a general definition of biotechnology, explains the "theory of colours" in market segmentation, and details the specific focus on marine biotechnology and SeaLife Pharma.
3. Austria: Analyzes the Austrian cultural and political landscape regarding biotechnology, using Hofstede's dimensions and public attitudes toward green biotechnology.
4. SeaLife Pharma enters into foreign markets: Evaluates potential market entry modes for the startup, recommending licensing or strategic alliances to mitigate risks associated with international expansion.
5. Conclusion: Summarizes the findings, highlighting the immense potential of SeaLife Pharma while emphasizing the necessity of strategic market analysis and risk management.
Keywords
Biotechnology, SeaLife Pharma, Marine Biotechnology, Blue Biotechnology, Market Entry Strategy, Licensing, Strategic Alliance, Hofstede, Austria, Antibiotics, Antimycotics, R&D, Socio-cultural, Sustainability, Pharmaceuticals.
Frequently Asked Questions
What is the primary focus of this paper?
The paper evaluates the challenges and strategic considerations for a specific Austrian biotechnology startup, SeaLife Pharma, regarding international expansion.
What are the central thematic fields covered in this study?
The study covers modern biotechnology sectors, marine research, cultural analysis based on Hofstede's dimensions, and international market entry strategies for small firms.
What is the ultimate objective of the author's research?
The goal is to determine the most effective and risk-averse strategy for SeaLife Pharma to enter foreign markets, given its current size and resource constraints.
Which scientific methods are employed in this analysis?
The paper utilizes a literature-based analysis of industry trends, statistical data from the OECD, and a case-study approach applied to the Austrian business context.
What does the main body of the paper discuss?
It covers the definition and potential of modern biotechnology, the specific business model of SeaLife Pharma, the cultural factors in Austria, and an assessment of entry strategies like licensing and alliances.
Which keywords best characterize this work?
Key terms include Biotechnology, Marine Biotechnology, Market Entry, Licensing, Strategic Alliance, and Socio-cultural factors.
Why is "blue biotechnology" considered a "white hope" for the industry?
It offers significant potential for discovering new, resilient antibiotics and sustainable biochemical processes in unexplored marine environments.
How do Hofstede’s cultural dimensions apply to SeaLife Pharma?
They are used to explain the Austrian business environment—such as the PDI, UAI, and MAS indices—which in turn influence the management structure and the cautious market approach of the company.
What is the final recommendation provided to SeaLife Pharma?
The author recommends that the firm should focus on licensing its patent rights and know-how to established European antibiotic or antimycotic producers to minimize operational risks.
- Quote paper
- Sebastian Maiwald (Author), 2010, The Entrance in Foreign Markets in the Field of Biotechnology and the Consideration of Socio-Cultural Particularities, Munich, GRIN Verlag, https://www.grin.com/document/145283
